Возможности транскраниальной сонографии в диагностике экстрапирамидных заболеваний

Обложка


Цитировать

Полный текст

Об авторах

Екатерина Юрьевна Федотова

ФГБНУ «Научный центр неврологии»

Email: sni@neurology.ru
ORCID iD: 0000-0001-8070-7644

д.м.н., рук. 5-го неврологического отделения

Россия, 125367, Москва, Волоколамское шоссе, д. 80

Андрей Олегович Чечёткин

ФГБНУ «Научный центр неврологии»

Email: sni@neurology.ru
ORCID iD: 0000-0002-8726-8928

д.м.н., зав. лаб. ультразвуковых методов исследования

Россия, Москва

Сергей Николаевич Иллариошкин

ФГБНУ «Научный центр неврологии»

Автор, ответственный за переписку.
Email: sni@neurology.ru
ORCID iD: 0000-0002-2704-6282

д.м.н., проф., член-корр. РАН, зам. директора по научной работе, рук. отдела исследований мозга

Россия, Москва

Список литературы

  1. Иллариошкин С.Н. Молекулярные основы болезни Паркинсона. В кн.: С.Н.Иллариошкин, Н.Н.Яхно (ред.) Болезнь Паркинсона и расстройства движений. Руководство для врачей. М., 2008: 8–17.
  2. Чечеткин А.О. Транскраниальное ультразвуковое сканирование мозга при болезни Паркинсона. Визуализация в клинике 2000; 17: 45–48.
  3. Чечеткин А.О., Реброва О.Ю. Отсутствие височных ультразвуковых окон — главное техническое ограничение для проведения транскраниального допплерографического исследования. Ультразвуковая и функциональная диагностика 2005; 3: 54–62.
  4. Экстрапирамидные расстройства: Руководство по диагностике и лечению (ред. В.Н. Шток, И.А. Иванова-Смоленская, О.С. Левин). М.: МЕДпресс-информ. 2002.
  5. Becker G., Berg D. Neuroimaging in basal ganglia disorders: Perspectives for transcranial ultrasound. Mov. Disord. 2001; 16: 23–32.
  6. Becker G., Seufert J., Bogdahn U. et al. Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial colorcoded real-time sonography. Neurology 1995; 45: 182–184.
  7. Behnke S., Berg D., Becker G. Does ultrasound disclose a vulnerability factor for Parkinson’s disease? J. Neurol. 2003; 250 (Suppl.1): 24–27.
  8. Behnke S., Berg D., Naumann M. et al. Differentiation of Parkinson’s disease and atypical parkinsonian syndromes by transcranial ultrasound. Neurol. Neurosurg. Psychiatry. 2005; 76: 423–425.
  9. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson’s disease: Implications for idiopathic and monogenetic forms. Neurochem. Res. 2007; 32: 1646–1654.
  10. Berg D. Transcranial ultrasound as a risk marker for Parkinson’s disease. Mov. Disord. 2009; 24 (Suppl.2): 677–683.
  11. Berg D., Behnke S., Walter U. Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall. Med. 2006; 27: 12–19.
  12. Berg D., Godau J., Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008; 7: 1044–1055.
  13. Berg D., Hochstrasser H. Iron metabolism in parkinsonian syndromes. Mov. Disord. 2006; 21: 1299–1310.
  14. Berg D., Merz B., Reiners K. et al. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov. Disord. 2005; 20: 383–385.
  15. Berg D., Roggendorf W., Schroeder U. et al. Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 2002; 59: 999–1005.
  16. Berg D., Seppi K., Liepelt I. et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov. Disord. 2010; 25: 1464–1469.
  17. Berg D., Siefker C., Becker G. Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J. Neurol. 2001; 248: 684–689.
  18. Berg D., Siefker C., Ruprecht-Dцrfler P. et al. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology. 2001; 56: 13–17.
  19. Dickson D.W., Braak H., Duda J.E. et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 2009; 8: 1150–1157.
  20. Doepp F., Plotkin M., Siegel L. et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson’s disease and essential tremor. Mov. Disord. 2008; 23: 405-410.
  21. Ebentheuer J., Canelo M., Trautmann E. et al. Substantia nigra echogenicity in progressive supranuclear palsy. Mov. Disord. 2010; 25: 773–777.
  22. Fasano M., Bergamasco B., Lopiano L. Modifications of the iron–neuromelanin system in Parkinson’s disease. J. Neurochem. 2006; 96: 909–916.
  23. Gaenslen A., Unmuth B., Godau J. et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson’s disease: a prospective blinded study. Lancet Neurol. 2008; 7: 417–424.
  24. Gaeta A., Hider R.C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 2005; 146: 1041–1059.
  25. Gaig C., Tolosa E. When does Parkinson’s disease begin? Movement Disorders. 2009; 24 (Suppl.2): 656–664.
  26. Hagenah J.M., Koenig I.R., Becker B. et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J. Neurol. 2007; 254: 1407–1413.
  27. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry. 2008; 79: 368–376.
  28. Kivi A., Trottenberg T., Kupsch A. Levodopa-responsive posttraumatic parkinsonism is not associated with changes of echogenicity of the substantia nigrа. Mov. Disord. 2005; 20: 258–262.
  29. Krogias C., Eyding J., Postert T. Transcranial sonography in Huntington’s disease. Int. Rev. Neurobiol. 2010; 90: 237–257.
  30. Krogias C., Postert T., Eyding J. Transcranial sonography in ataxia. Int. Rev. Neurobiol. 2010; 90: 217–235.
  31. Kwon D.-Y., Seo W.-K., Yoon H.-K. et al. Transcranial brain sonography in Parkinson’s disease with restless legs syndrome. Mov. Disord. 2010; 25: 1373–1378.
  32. Lesage S., Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009; 18: 48–59.
  33. Litvan I. Atypical Parkinsonian Disorders: Clinical and research aspects. New Jersey: Humana Press Inc., 2005.
  34. Mehnert S., Reuter I., Schepp K. et al. Transcranial sonography for diagnosis of Parkinson’s disease. BMC Neurol. 2010; 10: 9.
  35. Mijajlovic M., Dragasevic N., Stefanova E. et al. Transcranial sonography in spinocerebellar ataxia type 2. J. Neurol. 2008; 255: 1164–1167.
  36. Postuma R.B., Montplaisir J. Predicting Parkinson’s disease – why, when and how? Parkinsonism Relat. Disord. 2009; 15 (Suppl.3): 105–109.
  37. Puls I., Berg D., Maeurer M. et al. Transcranial sonography of the brain parenchyma: Comparison of B-mode imaging and tissue harmonic imaging. Ultrasound. Med. Biol. 2000; 26: 189–194.
  38. Rhodes S.L., Ritz B. Genetics of iron regulation and the possible role of iron in Parkinson’s disease. Neurobiol. Dis. 2008; 32: 183–195.
  39. Ruprecht-Doerfler P., Berg D., Tucha O. et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. NeuroImage. 2003; 18: 416–422.
  40. Schweitzer K.J., Bruessel T., Leitner P. et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson’s disease. J. Neurol. 2007; 254: 613–616.
  41. Schweitzer K.J., Hilker R., Walter U. et al. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov. Disord. 2006; 21: 94–98.
  42. Spiegel J., Hellwig D., Moellers M.-O. et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain. 2006; 129: 1188–1193.
  43. Stephenson R., Siderowf A., Stern M.B. Premotor Parkinson’s disease: clinical features and detection strategies. Mov. Disord. 2009; 24 (Suppl.2): 665–670.
  44. Stockner H., Sojer M., Seppi K. et al. Midbrain sonography in patients with essential tremor. Mov. Disord. 2007; 22: 414–417.
  45. Stockner H., Wurster I. Transcranial sonography in essential tremor. Int. Rev. Neurobiol. 2010; 90: 189–197.
  46. Tolosa E., Wenning G., Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006; 5: 75–86.
  47. Tsai C.-F., Wu R.-M., Huang Y.-W. et al. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson’s disease and vascular parkinsonism. J. Neurol. 2007; 254: 501–507.
  48. Vlaar A.M.M., Bouwmans A., Mess W.H. et al. Transcranial duplex in the differential diagnosis of parkinsonian syndromes. J. Neurol. 2009; 256: 530–538.
  49. Vlaar A.M.M., de Nijs T., van Kroonenburgh M.J.P.G. et al. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol. 2008; 8: 42.
  50. Walter U., Behnke S., Eyding J. et al. Transcranial brain parenchyma sonography in movement disorders: State of the art. Ultrasound. Med. Biol. 2007; 33: 15–25.
  51. Walter U., Dressler D., Lindemann C. et al. Transcranial sonography findings in welding-related parkinsonism in comparison to Parkinson’s disease. Mov. Disord. 2008; 23: 141–145.
  52. Walter U., Dressler D., Probst T. et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch. Neurol. 2007; 64: 1635–1640.
  53. Walter U., Dressler D., Wolters A. et al. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology. 2004; 63: 504–509.
  54. Walter U., Hoeppner J., Prudente-Morrissey L. et al. Parkinson’s disease- like midbrain sonography abnormalities are frequent in depressive disorders. Brain. 2007; 130: 1799–1807.
  55. Walter U., Klein C., Hilker R. et al. Brain parenchyma sonography detects preclinical parkinsonism. Mov. Disord. 2004; 19: 1445–1449.
  56. Walter U., Љkoloudнk D., Berg D. Transcranial sonography findings related to non-motor features of Parkinson’s disease. J. Neurol. Sci. 2010; 289: 123–127.
  57. Walter U., Wittstock M., Benecke R. et al. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J. Neural. Transm. 2002; 109: 191–196.
  58. Waters C.H. Diagnosis and management of Parkinson’s disease. Professional Communications, Inc., 2008.
  59. Zecca L., Berg D., Arzberger T. et al. In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage. Mov. Disord. 2005; 20: 1278–1285.
  60. Zecca L., Tampellini D., Gerlach M. et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behavior. J. Clin. Pathol.: Mol. Pathol. 2001; 54: 414–418.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Fedotova E.Y., Chechetkin A.O., Illarioshkin S.N., 2010

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах